Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

RBOT vs SYK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
RBOT
Vicarious Surgical Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$3M
5Y Perf.-99.8%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$112.69B
5Y Perf.+41.2%

RBOT vs SYK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
RBOT logoRBOT
SYK logoSYK
IndustryMedical - DevicesMedical - Devices
Market Cap$3M$112.69B
Revenue (TTM)$0.00$25.12B
Net Income (TTM)$-42M$3.25B
Gross Margin63.5%
Operating Margin22.4%
Forward P/E19.6x
Total Debt$8M$14.86B
Cash & Equiv.$3M$4.01B

RBOT vs SYKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

RBOT
SYK
StockSep 20May 26Return
Vicarious Surgical … (RBOT)1000.2-99.8%
Stryker Corporation (SYK)100141.2+41.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: RBOT vs SYK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: SYK leads in 5 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Vicarious Surgical Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
RBOT
Vicarious Surgical Inc.
The Growth Play

RBOT is the clearest fit if your priority is growth exposure.

  • EPS growth 21.2%
  • 31.5% revenue growth vs SYK's 11.2%
Best for: growth exposure
SYK
Stryker Corporation
The Income Pick

SYK carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 34 yrs, beta 0.55, yield 1.1%
  • 187.1% 10Y total return vs RBOT's -99.8%
  • Lower volatility, beta 0.55, Low D/E 66.3%, current ratio 1.89x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthRBOT logoRBOT31.5% revenue growth vs SYK's 11.2%
Quality / MarginsSYK logoSYK12.9% margin vs RBOT's 5.0%
Stability / SafetySYK logoSYKBeta 0.55 vs RBOT's 1.92, lower leverage
DividendsSYK logoSYK1.1% yield; 34-year raise streak; the other pay no meaningful dividend
Momentum (1Y)SYK logoSYK-22.5% vs RBOT's -94.1%
Efficiency (ROA)SYK logoSYK6.9% ROA vs RBOT's -164.5%, ROIC 11.4% vs -116.2%

RBOT vs SYK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

RBOTVicarious Surgical Inc.

Segment breakdown not available.

SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B

RBOT vs SYK — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSYKLAGGINGRBOT

Income & Cash Flow (Last 12 Months)

RBOT leads this category, winning 1 of 1 comparable metric.

SYK and RBOT operate at a comparable scale, with $25.1B and $0 in trailing revenue.

MetricRBOT logoRBOTVicarious Surgica…SYK logoSYKStryker Corporati…
RevenueTrailing 12 months$0$25.1B
EBITDAEarnings before interest/tax-$42M$6.3B
Net IncomeAfter-tax profit-$42M$3.2B
Free Cash FlowCash after capex-$40M$4.3B
Gross MarginGross profit ÷ Revenue+63.5%
Operating MarginEBIT ÷ Revenue+22.4%
Net MarginNet income ÷ Revenue+12.9%
FCF MarginFCF ÷ Revenue+17.1%
Rev. Growth (YoY)Latest quarter vs prior year+11.4%
EPS Growth (YoY)Latest quarter vs prior year+58.1%+56.0%
RBOT leads this category, winning 1 of 1 comparable metric.

Valuation Metrics

RBOT leads this category, winning 2 of 2 comparable metrics.
MetricRBOT logoRBOTVicarious Surgica…SYK logoSYKStryker Corporati…
Market CapShares × price$3M$112.7B
Enterprise ValueMkt cap + debt − cash$8M$123.5B
Trailing P/EPrice ÷ TTM EPS-0.06x35.03x
Forward P/EPrice ÷ next-FY EPS est.19.62x
PEG RatioP/E ÷ EPS growth rate2.36x
EV / EBITDAEnterprise value multiple20.31x
Price / SalesMarket cap ÷ Revenue4.49x
Price / BookPrice ÷ Book value/share0.30x5.02x
Price / FCFMarket cap ÷ FCF26.31x
RBOT leads this category, winning 2 of 2 comparable metrics.

Profitability & Efficiency

SYK leads this category, winning 6 of 8 comparable metrics.

SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-3 for RBOT. SYK carries lower financial leverage with a 0.66x debt-to-equity ratio, signaling a more conservative balance sheet compared to RBOT's 0.79x. On the Piotroski fundamental quality scale (0–9), SYK scores 6/9 vs RBOT's 1/9, reflecting solid financial health.

MetricRBOT logoRBOTVicarious Surgica…SYK logoSYKStryker Corporati…
ROE (TTM)Return on equity-3.3%+15.0%
ROA (TTM)Return on assets-164.5%+6.9%
ROICReturn on invested capital-116.2%+11.4%
ROCEReturn on capital employed-134.6%+13.0%
Piotroski ScoreFundamental quality 0–916
Debt / EquityFinancial leverage0.79x0.66x
Net DebtTotal debt minus cash$5M$10.8B
Cash & Equiv.Liquid assets$3M$4.0B
Total DebtShort + long-term debt$8M$14.9B
Interest CoverageEBIT ÷ Interest expense6.72x
SYK leads this category, winning 6 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

SYK leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in SYK five years ago would be worth $12,152 today (with dividends reinvested), compared to $16 for RBOT. Over the past 12 months, SYK leads with a -22.5% total return vs RBOT's -94.1%. The 3-year compound annual growth rate (CAGR) favors SYK at 1.8% vs RBOT's -80.2% — a key indicator of consistent wealth creation.

MetricRBOT logoRBOTVicarious Surgica…SYK logoSYKStryker Corporati…
YTD ReturnYear-to-date-80.6%-15.2%
1-Year ReturnPast 12 months-94.1%-22.5%
3-Year ReturnCumulative with dividends-99.2%+5.5%
5-Year ReturnCumulative with dividends-99.8%+21.5%
10-Year ReturnCumulative with dividends-99.8%+187.1%
CAGR (3Y)Annualised 3-year return-80.2%+1.8%
SYK leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

SYK leads this category, winning 2 of 2 comparable metrics.

SYK is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than RBOT's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SYK currently trades 72.7% from its 52-week high vs RBOT's 3.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricRBOT logoRBOTVicarious Surgica…SYK logoSYKStryker Corporati…
Beta (5Y)Sensitivity to S&P 5001.92x0.55x
52-Week HighHighest price in past year$13.75$404.87
52-Week LowLowest price in past year$0.35$289.91
% of 52W HighCurrent price vs 52-week peak+3.6%+72.7%
RSI (14)Momentum oscillator 0–10030.024.3
Avg Volume (50D)Average daily shares traded24K2.1M
SYK leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

SYK is the only dividend payer here at 1.14% yield — a key consideration for income-focused portfolios.

MetricRBOT logoRBOTVicarious Surgica…SYK logoSYKStryker Corporati…
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$403.69
# AnalystsCovering analysts50
Dividend YieldAnnual dividend ÷ price+1.1%
Dividend StreakConsecutive years of raises34
Dividend / ShareAnnual DPS$3.36
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

SYK leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). RBOT leads in 2 (Income & Cash Flow, Valuation Metrics).

Best OverallStryker Corporation (SYK)Leads 3 of 6 categories
Loading custom metrics...

RBOT vs SYK: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is RBOT or SYK a better buy right now?

Stryker Corporation (SYK) offers the better valuation at 35.

0x trailing P/E (19. 6x forward), making it the more compelling value choice. Analysts rate Stryker Corporation (SYK) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — RBOT or SYK?

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -99. 8% for Vicarious Surgical Inc. (RBOT). Over 10 years, the gap is even starker: SYK returned +187. 1% versus RBOT's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — RBOT or SYK?

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

55β versus Vicarious Surgical Inc. 's 1. 92β — meaning RBOT is approximately 251% more volatile than SYK relative to the S&P 500. On balance sheet safety, Stryker Corporation (SYK) carries a lower debt/equity ratio of 66% versus 79% for Vicarious Surgical Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — RBOT or SYK?

On earnings-per-share growth, the picture is similar: Vicarious Surgical Inc.

grew EPS 21. 2% year-over-year, compared to 8. 2% for Stryker Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — RBOT or SYK?

Stryker Corporation (SYK) is the more profitable company, earning 12.

9% net margin versus 0. 0% for Vicarious Surgical Inc. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus 0. 0% for RBOT. At the gross margin level — before operating expenses — SYK leads at 64. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — RBOT or SYK?

In this comparison, SYK (1.

1% yield) pays a dividend. RBOT does not pay a meaningful dividend and should not be held primarily for income.

07

Is RBOT or SYK better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). Vicarious Surgical Inc. (RBOT) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, RBOT: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between RBOT and SYK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

SYK pays a dividend while RBOT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

RBOT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.